Among the 3.5 million food and beverage items listed in the Open Food Facts World database in 2024, more than 139,000 contain at least one food colouring additive and more than 700,000 contain at least one preservative. Three new studies show links between the consumption of these additives and an increased risk of cancer, type 2 diabetes, cardiovascular disease, and hypertension. This research is conducted by a team of...
Published in the journal Nature, the NIVIPIT study, led by Gustave Roussy and conducted by researchers from Inserm and the University of Paris-Saclay, demonstrates the benefit — in terms of both efficacy and safety — of administering an immunotherapy treatment intratumorally that is typically given intravenously. This approach, carried out via interventional radiology — a field in which Gustave Roussy is a leading actor — involves injecting the treatment...
Pancreatic cancer, which affects a growing number of patients, remains one of the most aggressive forms due to the ability of cancer cells to resist traditional treatments such as chemotherapy.
BIOMEDE 1.0, sponsored and coordinated by Gustave Roussy, is the largest clinical trial ever conducted in diffuse intrinsic pontine glioma, an aggressive paediatric cancer in which survival rarely exceeds one year. The findings, published in the journal Nature Medicine, chart a new biological map of the disease, identify patient response biomarkers, and document the prolonged survival of four children — opening concrete avenues for the therapies of tomorrow. This...
A study conducted by Institut Curie and Inserm reveals that the presence of a compound present in cruciferous vegetables, indole-3-carbinol, is essential to make certain cancer treatments effective.
While the role of certain air pollutants is now recognized in some cancers in adults, it has not yet been established in the case of acute leukemia in children. A team of researchers from Inserm, in collaboration with Sorbonne Paris Nord University, Paris Cité University, INRAE and Swiss researchers, used data from the GEOCAP-Birth study based on the national registry of childhood cancer to assess the risk of acute...
What if vaccination could be administered by simple skin application rather than injection? A team of researchers from Inserm, Institut Curie, and King's College London investigated the impact of external mechanical constraints (skin stretching, friction, etc.) on skin impermeability in animals and humans.
A new study, published in Nature Medicine, highlights the efficacy of patritumab deruxtecan (HER3-DXd), an antibody HER3-directed-drug conjugate (ADC), in patients with hormone receptor-positive metastatic breast cancer who had already received multiple treatments, including hormone therapy, chemotherapy, and targeted therapies.
A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed by scientists at Institut Curie, the CNRS, and Inserm.
Nearly one in three cancers develops following chronic inflammation, whose origin remains unclear. In a new study, researchers from Inserm, CNRS, Université Claude-Bernard Lyon 1 and the Léon Bérard Centre at the Cancer Research Center of Lyon identified lymphocytes involved in the inflammatory processes and that are thought to be implicated in the generation of these cancers. This research opens up new avenues in terms of prevention and treatment.
Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG), and Inserm has made a breakthrough by identifying some of the genetic and energetic characteristics of these stem cells. Notably, a specific iron utilisation process.
